BioNTech's Seoul Moment: Can Two Antibodies Carry a Story That COVID Revenue No Longer Supports?

BioNTech's Q2 revenue fell to €105.6M, net loss €820.8M; 2026 sales forecast cut. Lung cancer data at IASLC Seoul may shift narrative.

The numbers tell a stark story. BioNTech's second-quarter revenue collapsed to €105.6 million from €260.8 million a year earlier, the net loss stretched to €820.8 million, and management has slashed its 2026 sales forecast to €1.6–1.9 billion from an earlier €2.0–2.3 billion range. The COVID vaccine franchise that built the company is eroding faster than almost anyone on the Street anticipated.

Yet when the company steps onto the podium at the IASLC World Conference on Lung Cancer in Seoul from September 12–15, the narrative shifts away from the shrinking vaccine business entirely. BioNTech will present first-time global lung cancer data on pumitamig combined with the antibody-drug conjugate elfetabart drozuntecan, alongside updated survival figures from the Phase 3 PRESERVE-003 study of gotistobart. For a company whose oncology story has taken repeated hits, this is the moment the pipeline has to speak for itself.

A Pipeline That Just Lost a Candidate

The stakes in Seoul are higher because of what happened in late August. BioNTech terminated the Phase 2 trial BNT122-01 of autogene cevumeran in colorectal cancer patients after an independent data monitoring committee flagged a numerical imbalance in overall survival between treatment arms and concluded continued enrollment was unlikely to prove fruitful. No new safety signals emerged, and the parallel Phase 2 study of the same candidate in pancreatic cancer continues unchanged — but the setback removed a prominent name from an oncology pipeline that BioNTech has positioned as its growth engine beyond COVID.

That engine now carries more weight than ever. The company's cash position of €16.6 billion at the end of the second quarter buys time — a point no one disputes. But as the cevumeran halt demonstrated, time does not substitute for regulatory approval or commercial revenue.

Wall Street's Patience Wears Thin

The market's response to the converging pressures has been telling. On September 8, BMO Capital downgraded BioNTech from Outperform to Market Perform, cutting its price target from $128 to $105. The rationale: a sharper-than-expected erosion of Comirnaty sales and an absence of "de-risking data" for pumitamig until 2028. Canaccord Genuity had already trimmed its target to $136 in late August but maintained a Buy rating — evidence that analysts remain split on how to read the transition.

The bearish camp points to a bundle of unresolved risks beyond the revenue slide. Arbutus Biopharma and its exclusive licensee Genevant Sciences filed three international lawsuits in July against Pfizer and BioNTech, seeking to enforce patent rights on the lipid nanoparticle technology used to deliver mRNA vaccines. The litigation is pending, not decided — a procedural step rather than a judgment — but a favorable outcome for the plaintiffs could mean licensing payments or distribution restrictions down the line.

Meanwhile, the adjusted net loss of €562.3 million in the second quarter underscores that the cost base is not shrinking in step with revenue. Add a 30-day volatility reading of 72% and the picture is one of an investor base braced for movement in either direction.

The Bull Case Hinges on Data

The optimistic scenario is straightforward: convincing survival data from pumitamig and gotistobart in Seoul could flip the narrative from a company defined by its shrinking vaccine franchise to one validated in oncology with deep pockets to fund the journey. Management's active share buyback program of up to $1 billion signals that the board considers the current valuation attractive.

There is also the leadership transition to factor in. Guido Oelkers, arriving from Swedish Orphan Biovitrum, is slated to take over as CEO no later than February 1, 2027, while Özlem Türeci moves to a new independent company she will co-lead with Ugur Sahin. The structural overhaul carries a long horizon — not the stuff of short-term price catalysts, but a signal of strategic intent that some investors may read favorably.

A Stock Caught Between Two Averages

The share price itself reflects the indecision. Trading at €83.85–84.35, BioNTech sits roughly 20–21% below its 52-week high of €105.80 reached in January, yet about 23% above the March low. Notably, the 50-day moving average of €84.14 and the 200-day average of €84.16 sit almost exactly at the current price level — a textbook consolidation pattern that suggests the market is waiting for direction rather than choosing one.

The Seoul data will likely provide that direction. If the lung cancer programs deliver, the combination of a deep cash pile, a shrinking share count from the buyback, and a validated oncology story could push the stock decisively out of its trading range. If the data disappoint, the erosion narrative — already reinforced by the downgrade and the forecast cut — will harden.

Between now and the conference presentations, the risks arguably outweigh the rewards. But the gap between the two is narrowing, and Seoul will determine which way it closes.